Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases

Phan, C.; Sigal, M.-L.; Lhafa, M; Barthélémy, H.; Maccari, F.; Estève, É.; Réguiai, Z.; Perrot, Jean‐Luc; Chaby, G.; Maillard, H.; Bégon, É.; Alexandre, M.; Toussaint, Paul; Bastien-Jacquin, M; Bravard, P.; Sauque, E; Quatrebarbes, Julie De; Pfister, Pierrette Baschung; Beauchet, Alain; Mahé, E.; Resopso, Gem

doi:10.1016/j.annder.2015.06.024

Cited by 32 publications

(29 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presence of MetS and/or PsA differs according to disease severity . Additionally, according to the published work, 8.3%, 18.4%, 19.6% and 20.0% of patients with plaque psoriasis had comorbid diabetes, obesity, hypertension and dyslipidemia, respectively …”

Section: Introductionmentioning

confidence: 99%

“…[19][20][21] Additionally, according to the published work, 8.3%, 18.4%, 19.6% and 20.0% of patients with plaque psoriasis had comorbid diabetes, obesity, hypertension and dyslipidemia, respectively. 22 There is an increasing interest within the Brazilian research community to identify the comorbidities associated with PsO and understand the effect of the disease on quality of life. However, this subject is still scarcely researched.…”

Section: Introductionmentioning

confidence: 99%

“… Table S1. Components of metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III criteria Table S2. Logistic regression model for psoriatic arthritis (first model, n = 275) Table S3.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Souza

Castro

Carneiro

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Interest has increased in comorbidities associated with psoriasis and their effects on health‐related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross‐sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [ DLQI ], 36‐Item Short Form Health Survey [SF‐36] and EuroQol Five‐Dimension Questionnaire Three‐Level version [ EQ ‐5D‐3L]). Physical examination and several tests to assess desired outcomes were performed by a dermatologist and a rheumatologist during three visits. The prevalence of MetS and PsA was 50.0% and 41.8%, respectively. Dyslipidemia was the most prevalent (74.5%) secondary comorbidity, followed by hypertension (61.8%), obesity (52.5%) and T2DM (30.9%). The mean (standard deviation) DLQI score was 6.5 (6.9), and mean physical and mental SF‐36 measures were 45.2 (10.4) and 45.5 (12.3), respectively, and for EQ‐5D‐3L, mean utility index and EQ ‐ VAS scores were 0.68 (0.27) and 72.7 (19.7), respectively. PsA and MetS are important comorbidities; a reduced HRQoL is noted among plaque psoriasis patients with these comorbidities, emphasizing the relevance of diagnosis and treatment beyond the care of skin lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Souza

Castro

Carneiro

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…A large number of epidemiological studies not only have shown an increased prevalence of cardiovascular risk factors, hypertension and CVD, like myocardial infarction and cerebrovascular disease in psoriasis, but also have identified psoriasis as an independent risk factor for developing CVD …”

Section: Introductionmentioning

confidence: 99%

“…Reciprocally, proinflammatory cytokines and hormones produced in conditions like obesity, atherosclerosis and diabetes may impact the pathogenesis of psoriasis by promoting a proinflammatory state that elevates the susceptibility to the development or worsening of existing psoriasis. 4 A large number of epidemiological studies not only have shown an increased prevalence of cardiovascular risk factors, hypertension [6][7][8][9][10][11] and CVD, [12][13][14][15] like myocardial infarction and cerebrovascular disease 6,14,[16][17][18][19][20] in psoriasis, but also have identified psoriasis as an independent risk factor for developing CVD. 12,21 Furthermore, a large body of evidence revealed that psoriasis is related to obesity 7,[22][23][24][25] and especially central obesity.…”

Section: Introductionmentioning

confidence: 99%

Psoriasis, cardiovascular risk factors and metabolic disorders: sex‐specific findings of a population‐based study

Sondermann

Deudjui

Körber³

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Scientific evidence suggests an association between psoriasis and cardiovascular and metabolic diseases. However, there are hardly any sex‐specific results from population‐based studies reporting the prevalence of cardiovascular risk factors in patients with psoriasis and point estimates of the association between psoriasis and cardiovascular and metabolic disorders. Objective Aims are to evaluate the sex‐specific prevalence of psoriasis and cardiovascular risk factors, and to estimate sex‐specific associations between psoriasis and diabetes type 2 (DM) and metabolic syndrome (MetS). Methods We used data of 3723 participants (45–75 years, 54.1% women) without coronary heart disease and missing data (psoriasis, DM, MetS) from the Heinz Nixdorf Recall study. Standardized information on health outcomes and risk factors was assessed. We performed descriptive statistics and multiple regression analyses to calculate prevalence rate ratios (PR) and 95% confidence intervals (95% CI). Results The prevalence of psoriasis was 3.8% (n = 143), with no differences between sex. We observed more often metabolic and cardiovascular risk factors in women with psoriasis compared to women without psoriasis. Interestingly, in men, this pattern was partly reversed. Multiple regression analyses revealed distinctly elevated PRs for DM for both women and men with psoriasis (fully adjusted PR: 2.43; 95% CI: 1.17–5.07, resp. 2.09; 1.16–3.76). Regarding the MetS, the results were inconsistent, showing a positive association between psoriasis and MetS in women (1.84; 1.14–2.98), but a negative association in men, even though with a wide 95% CI (0.69; 0.42–1.12). Conclusion The results of our cross‐sectional, population‐based analysis show a distinct association between psoriasis and DM, whereas for the MetS the results contrasted between men and women, translating in women with MetS showing a higher and in men a lower chance to be psoriatic. Our results emphasize the urgent need for sex‐specific research, studying the effects of psoriasis on metabolic disorders as well as effective sex tailored prevention measures.

show abstract

Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis

et al. 2017

View full text Add to dashboard Cite

We used a southern Swedish cohort of psoriasis (PSO) and psoriatic arthritis (PsA) patients and population-based referents (N = 57,800) to investigate the influence of socioeconomic and demographic factors on the probability of healthcare use and on healthcare costs when controlling for need as measured by PSO/PsA and common additional morbidities such as diabetes, depression and myocardial infarction. People with PSO/PsA were identified by ICD-10 codes in the Skåne Healthcare Register 1998–2007. Resource use and costs for years 2008–2011 were retrieved from the Skåne Healthcare Register and the Swedish Prescribed Drug Register, and socioeconomic data were retrieved from Statistics Sweden. After controlling for PSO/PsA and common additional morbidities, income, and to some extent education, had significant effects on the probability of five types of healthcare use. Overall, income showed a bell-shaped relationship to healthcare costs, with patients in income quintiles 2 and 3 having the highest mean annualized cost irrespective of model specification. Education did not have a significant effect in most specifications. Analyses including interaction effects indicated similarly higher costs across income quintiles in the PSO and PsA subgroups, though these cost differences were lower in magnitude for patients with PSO in quintile 5 and with PsA in quintile 1. In conclusion, our results show persistent socioeconomic disparities in healthcare use among a cohort of chronically ill patients and referents, even after controlling for the presence of PSO/PsA and common additional morbidities. These disparities persist even in a country with general healthcare coverage and low out-of-pocket payments.Electronic supplementary materialThe online version of this article (doi:10.1007/s10198-017-0895-5) contains supplementary material, which is available to authorized users.

show abstract

Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases

Cited by 32 publications

References 36 publications

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Psoriasis, cardiovascular risk factors and metabolic disorders: sex‐specific findings of a population‐based study

Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis

Contact Info

Product

Resources

About